A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD).

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD).

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Vortioxetine (Primary) ; Duloxetine
  • Indications Cognition disorders; Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms CONNECT
  • Sponsors Takeda
  • Most Recent Events

    • 04 Feb 2016 According to Lundbeck media release, FDA Psychopharmacologic Drug Advisory Committee supports the effectiveness of Brintellix and reviewed data from this trial.
    • 03 Feb 2016 Results published in Lundbeck media release.
    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top